Rangarao Sai 4/A

What Happened

• Rangarao Sai, Chief Commercial Officer of Pelthos Therapeutics (PTHS), was granted 30,518 restricted stock units (RSUs) on 2025-07-02. The RSUs were granted at $0.00 (no cash paid) and are reported as an award/grant (transaction code A). This filing is an amendment that moves the original disclosure into Table I of the Form 4.

Key Details

• Transaction date: 2025-07-02; amended Form 4 filed: 2026-04-01.
• Grant size: 30,518 RSUs; reported acquisition price: $0.00; economic value at grant: $0 (face amount reported).
• Vesting: 1/3 vests on July 2, 2026; remaining 2/3 vest in equal quarterly installments over the following two years, contingent on continued service.
• Settlement: RSUs may be settled solely in shares of common stock (one RSU = one share upon settlement).
• Footnote: Original grant was reported in Table II of the prior Form 4; this amendment reports it in Table I (administrative reporting change).
• Shares owned following the transaction are not specified in this amendment.
• Exhibit included: Exhibit 24 (Power of Attorney).

Context

• This was a compensation grant to an officer, not an open-market purchase or sale; such awards are routine for employee retention and do not by themselves indicate a buy/sell signal. The RSUs vest over time, so any future sales or ownership changes will depend on vesting and potential tax-withholding arrangements.